Diagnóstico y tratamiento | 16 ABR 21

Espectro clínico de la enfermedad de Alzheimer

Es la causa más común de deterioro cognitivo o demencia en personas > 65 años
Autor/a: Alireza Atri Med Clin N Am 103 (2019) 263.293.
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas
  1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet 2017;390(10113):2673–734.
  2. Deschaintre Y, Richard F, Fau-Leys D, et al. Treatment of vascular risk factors is associated with slower decline in Alzheimer’s disease. Neurology 2009;73(9): 674–80.
  3. Atri A. Alzheimer’s disease and Alzheimer’s dementia. In: Dickerson BC, Atri A, editors. Dementia: comprehensive principles and practices. 1st edition. New York: Oxford University Press; 2014. p. 360–432.
  4. Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement 2018;14(3):367–429.
  5. Prince MJ, Wimo A, Guerchet MM, et al. World alzheimer report 2015 - the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease International (ADI); 2015.
  6. Prince M, Prina M, Guerchet M. The world Alzheimer report 2013 ‘Journey of Caring: an analysis of long-term care for dementia’. Alzheimer’s Disease International (ADI); 2013.
  7. Wimo A, Prince M. The world Alzheimer report 2010 ‘The Global Impact of Dementia. Alzheimer’s Disease International (ADI); 2010.
  8. Saxena S. Dementia world report: a public health priority. World Health Organization (WHO); 2012.
  9. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol 2017;134(2):171–86.
  10. Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 2013;9(1):e-1-16.
  11. Simonsen AH, Herukka SK, Andreasen N, et al. Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement 2017; 13(3):274–84.
  12.  Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018;90(3):126–35.
  13. Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 2013;80(19):1778–83.
  14. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006;112:389–404.
  15. Jellinger KA, Bancher C. Neuropathology of Alzheimer’s disease: a critical update. J Neural Transm 1998;54:77–95.
  16.  Parvizi J, Van Hoesen GW, Damasio A. The selective vulnerability of brainstem nuclei to Alzheimer’s disease. Ann Neurol 2001;49:53–66.
  17. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012;8(1):1–13.
  18. Jack C, Knopman D, Jagust W, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet 2010;9(1):119–28.
  19. Attems J, Jellinger K, Thal DR, et al. Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 2011;37:75–93.
  20. Atri A, Locascio JJ, Lin JM, et al. Prevalence and effects of lobar microhemorrhages in early-stage dementia. Neurodegener Dis 2005;2(6):305–12.
  21. Loy CT, Schofield PR, Turner AM, et al. Genetics of dementia. Lancet 2014; 383(9919):828–40.
  22. Bertram L, McQueen MB, Mullin K, et al. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39(1):17–23.
  23. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261(5123):921–3.
  24. Davies P. A very incomplete comprehensive theory of Alzheimer’s disease. Ann N Y Acad Sci 2000;924:8–16.
  25. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 2011;12(12):723–38.
  26. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011;68(8):1062–4.
  27. Selkoe DJ, Abraham CR, Podlisny MB, et al. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer’s disease. J Neurochem 1986;46(6):1820–34.
  28. Haass C, Koo EH, Mellon A, et al. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992;357(6378):500–3.
  29. Selkoe DJ. Amyloid protein and Alzheimer’s disease. Sci Am 1991;265(5): 68–71, 74–6, 78.
  30. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256(5054):184–5.
  31. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353–6.
  32. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):263–9.
  33. Petersen RC, Aisen P, Boeve BF, et al. Criteria for mild cognitive impairment due to Alzheimer’s disease in the community. Ann Neurol 2013;74(2):199–208.
  34. Chhatwal JP, Schultz AP, Johnson KA, et al. Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing. Brain 2018;141(5): 1486–500.
  35. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med 2007;120(5):388–97.
  36. Jost BC, Grossberg GT. The natural history of Alzheimer’s disease: a brain bank study. J Am Geriatr Soc 1995;43(11):1248–55.
  37. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer’s disease: a natural history study. J Am Geriatr Soc 1996;44(9):1078–81.
  38. Alzheimer’s-Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement 2013;9(2):208–45.
  39. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9(11):1118–27.
  40. Dubois B, Feldman H, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6(8):734–46.
  41. APA. Diagnostic and statistical manual of mental disorders - (DSM-V). 5th edition. Washington, DC: American Psychiatric Publishing; 2013.
  42. Atri A, Norman M, Knopman D, et al. Alzheimer’s association best clinical practice guidelines for the evaluation of neurodegenerative cognitive behavioral syndromes, Alzheimer’s disease and dementias in the United States. Alzheimer’s Association International Conference. Chicago, 22 July, 2018.
  43. Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology 2005;65(4):559–64.
  44. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60(4):616–31.
  45. Rosenbloom MH, Atri A. The evaluation of rapidly progressive dementia. Neurologist 2011;17(2):67–74.
  46. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71(12):903–10.
  47. Atri A. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice. Handb Clin Neurol 2016;136: 971–84.
  48. Cordell CB, Borson S, Boustani M, et al. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement 2013; 9(2):141–50.
  49. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008;115(4):427–36.
  50. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69(24):2197–204.
  51. Bhalerao S, Seyfried LS, Kim HM, et al. Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder. J Geriatr Psychiatry Neurol 2012;25(1): 29–36.
  52. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers (NG97). NICE, UK, June 20, 2018.
  53. Okura T, Plassman BL, Steffens DC, et al. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc 2012;59(3):473–81.
  54. Kales HC, Chen P, Blow FC, et al. Rates of clinical depression diagnosis, functional impairment, and nursing home placement in coexisting dementia and depression. Am J Geriatr Psychiatry 2005;13(6):441–9.
  55. Ballard C, Corbett A, Howard R. Prescription of antipsychotics in people with dementia. Br J Psychiatry 2014;205(1):4–5.
  56. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ 2015;350:h369.
  57. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA 2012;308(19):2020–9.
  58. Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008;168(5): 508–13.
  59. Fong TG, Davis D, Growdon ME, et al. The interface between delirium and dementia in elderly adults. Lancet Neurol 2015;14(8):823–32.
  60. Oh ES, Fong TG, Hshieh TT, et al. Delirium in older persons: advances in diagnosis and treatment. JAMA 2017;318(12):1161–74.
  61. Schmidt R, Hofer E, Bouwman FH, et al. EFNS-ENS/EAN guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015;22(6):889–98.
  62. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J 2012;15(4):120–6.
  63. Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013;5(1):6–16.
  64. Tricco AC, Ashoor HM, Soobiah C, et al. Comparative effectiveness and safety of cognitive enhancers for treating alzheimer’s disease: systematic review and network metaanalysis. J Am Geriatr Soc 2018;66(1):170–8.
  65. Rountree SD, Atri A, Lopez OL, et al. Effectiveness of antidementia drugs in delaying Alzheimer disease progression. Alzheimers Dement 2013;9(3):338–45.
  66. Cappell J, Herrmann N, Cornish S, et al. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer’s disease. CNS Drugs 2010;24(11): 909–27.
  67. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 study group. Neurology 2000;54:2261–8.
  68. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 2004;363(9427):2105–15.
  69. Doody R, Geldmacher D, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58(3):427–33.
  70. Farlow M, Anand R, Messina J Jr, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000;44(4):236–41.
  71. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 2012;366(10):893–903.
  72. Howard R, McShane R, Lindesay J, et


Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023